UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 134

Sortiert nach

A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome

Radiotherapy and oncology, 2021-02, Vol.155, p.232-236

2021

Volltextzugriff (PDF)

Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: “Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up” by Huguet et al

Annals of oncology, 2024-08, Vol.35 (8), p.749-750

2024

Volltextzugriff (PDF)

Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275)

Clinical & experimental metastasis, 2021-10, Vol.38 (5), p.451-458

2021

Volltextzugriff (PDF)

Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate Cancer

Clinical oncology (Royal College of Radiologists (Great Britain)), 2018-02, Vol.30 (2), p.93-100

2018

Volltextzugriff (PDF)

Palliative radiotherapy in older adults with head and neck squamous cell carcinoma: A systematic review

Oral oncology, 2021-08, Vol.119, p.105355-105355, Article 105355

2021

Volltextzugriff (PDF)

Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years

Clinical oncology (Royal College of Radiologists (Great Britain)), 2022-01, Vol.34 (1), p.50-56

2022

Volltextzugriff (PDF)

Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer

Clinical & translational oncology, 2022-07, Vol.24 (7), p.1395-1402

2022

Volltextzugriff (PDF)

Limits of dose constraint definition for organs at risk specific to stereotactic radiotherapy

Cancer radiothérapie, 2023-06, Vol.27 (4), p.341

2023

Volltextzugriff (PDF)

Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy?

Cancer radiothérapie, 2022-10, Vol.26 (6-7), p.858-864

2022

Volltextzugriff (PDF)

Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer

Clinical & translational oncology, 2019-07, Vol.21 (7), p.933-938

2019

Volltextzugriff (PDF)

Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs

Expert review of anticancer therapy, 2020-09, Vol.20 (9), p.743-753

2020

Volltextzugriff (PDF)

Two cases of Hemosuccus pancreaticus after stereotactic radiotherapy to the pancreas: A case study

Cancer radiothérapie, 2020-02, Vol.24 (1), p.60-63

2020

Volltextzugriff (PDF)

Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives

Clinical and translational radiation oncology, 2018-03, Vol.10, p.13-22

2018

Volltextzugriff (PDF)

Robotic stereotactic treatment for malignant metastasis of solid tumour in the pancreas: A multiple case report and review of literature

Cancer radiothérapie, 2017-12, Vol.21 (8), p.784-787

2017

Volltextzugriff (PDF)

Fulvestrant – ready to start its journey in the breast cancer adjuvant endocrine world?

European journal of cancer (1990), 2005-02, Vol.41 (3), p.341-343

2005

Volltextzugriff (PDF)

Metabolic features of cancer cells impact immunosurveillance

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002362

2021

Volltextzugriff (PDF)

Single-Fraction Radiotherapy (SFRT) For Bone Metastases: Patient Selection And Perspectives

Cancer management and research, 2019-01, Vol.11, p.9397-9408

2019

Volltextzugriff (PDF)

Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer

Cancer investigation, 2019-01, Vol.37 (1), p.29-38

2019

Volltextzugriff (PDF)

The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation

Technology in cancer research & treatment, 2020, Vol.19, p.1533033820980412-1533033820980412

2020

Volltextzugriff (PDF)

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints

The lancet oncology, 2012-06, Vol.13 (6), p.e240-e248

2012

Volltextzugriff (PDF)

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types

The lancet oncology, 2011-11, Vol.12 (12), p.1162-1168

2011

Volltextzugriff (PDF)

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Annals of oncology, 2014-08, Vol.25 (8), p.1544-1550

2014

Volltextzugriff (PDF)

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226

2022

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(124)

Publikationsform

Artikel
(133)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(133)
Life Sciences & Biomedicine
(131)
Humans
(103)
Female
(74)
Middle Aged
(35)
Tumors
(34)
Breast Cancer
(33)
Adult
(31)
Aged
(31)
Prognosis
(29)
Breast Neoplasms - Drug Therapy
(28)
Breast Neoplasms - Pathology
(23)
Breast Neoplasms - Genetics
(22)
Male
(22)
Biological And Medical Sciences
(21)
Disease-Free Survival
(21)
Medical Sciences
(20)
Animals
(19)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(18)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome

Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: “Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up” by Huguet et al

Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275)

Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate Cancer

Palliative radiotherapy in older adults with head and neck squamous cell carcinoma: A systematic review

Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years

Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer

Limits of dose constraint definition for organs at risk specific to stereotactic radiotherapy

Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy?

Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer

Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs

Two cases of Hemosuccus pancreaticus after stereotactic radiotherapy to the pancreas: A case study

Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives

Robotic stereotactic treatment for malignant metastasis of solid tumour in the pancreas: A multiple case report and review of literature

Fulvestrant – ready to start its journey in the breast cancer adjuvant endocrine world?

Metabolic features of cancer cells impact immunosurveillance

Single-Fraction Radiotherapy (SFRT) For Bone Metastases: Patient Selection And Perspectives

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer

The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Aktive Filter

Suchergebnisse filtern